key: cord-0696724-xg8tmibr
authors: Ma, Qinhai; Pan, Weiqi; Li, Runfeng; Liu, Bin; Li, Chufang; Xie, Yuqi; Wang, Zhoulang; Zhao, Jin; Jiang, Haiming; Huang, Jicheng; Shi, Yongxia; Dai, Jun; Zheng, Kui; Li, Xiaobo; Yang, Zifeng
title: Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
date: 2020-04-30
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104850
sha: 69382cbac0bbdd2437414b92b122815b44d4cf46
doc_id: 696724
cord_uid: xg8tmibr

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host’s immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.

Coronaviruses (CoVs) are a group of enveloped viruses named for their coronary appearance with positive single-stranded RNA genomes that infect animal hosts [1] . Many of the coronaviruses were recognized as viruses typically causing pneumonia and colds until the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 from zoonotic sources [2] . In addition, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing severe acute respiratory disease emerged recently in Wuhan, China in December 2019 [3, 4] . Like the other two highly pathogenic coronaviruses SARS-CoV and MERS-CoV, SARS-CoV-2 can also cause severe respiratory illness and even death. Moreover, the population's susceptibility to these highly pathogenic coronaviruses has contributed to large outbreaks and evolved into the public health events, highlighting the necessity to prepare for the future emerging viruses [5] .

Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 spreads rapidly among humans and likely originates in bats [3, 6] . The initial patient cluster with confirmed SARS-CoV-2 infection was reported as pneumonia with unknown aetiology, which bore some resemblance to both SARS-CoV and MERS-CoV infections and was associated with ICU admission and high mortality. Moreover, patients requiring ICU admission had higher concentrations of G-CSF, IP-10, MCP-1, MIP-1A, and TNF-α than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity [7] . To date the severity of SARS-CoV-2 has tended to be mild, the risk of fatality among hospitalized cases was 4.3% in a single-center case series of 138 hospitalized patients [8] , and the infection fatality risk could be below 1% or even below 0.1% in a large number of undetected relatively mild infections [9] . However, the basic reproduction number (R0) of person-to-person spread was about 2.6, which meant that the cases of infection would grow at an exponential rate. As of 7 February, 2020, 57,620 cases of SARS-CoV-2 have been reported in China, including 26,359 suspected cases, and a sustained increase is predicted. It is challenging to judge the severity and predict the consequences of the information available to date. Since no specific antiviral treatment for SARS-CoV-2 infection is currently available, supportive cares, including symptomatic controls and prevention of complications remain the most important management strategy, especially in preventing acute respiratory distress syndrome [4, 10] . Currently, there is no special antiviral treatment or vaccine J o u r n a l P r e -p r o o f against the new virus. Therefore, it is of great importance to research and develop effective and safe antiviral drugs.

It has been reported that many traditional Chinese medicine (TCM) prescriptions could not only inhibit the replication of virus directly, but also attenuate excessive pro-inflammatory responses and tissue damage by viruses [11] [12] [13] . Therefore, it is significantly to study the traditional Chinese medicines that have obvious advantages in the treatment of the new virus. Liu Shen capsule (LS), a traditional Chinese medicine, has been used to treat influenza, tonsillitis, pharyngitis, and mumps for more than a century [14] . It consists of Bezoar (the gall-stone of Bos taurus domesticus Gmelin), Musk (the excretion of Moschus), cinobufagin venom toad (the excretion of Venenum Bufonis), pearl (the shell of Pernulo), realgar, and borneol. In previous studies, it was shown that the LS exhibited a wide spectrum of pharmacological properties, such as anti-inflammatory, anticancer, antiviral, analgesic, antibacterial, and immunomodulatory activities [15, 16] . In addition, LS could inhibit viral propagation and regulate immune function and achieved similar therapeutic effectiveness with oseltamivir in reducing the course of H1N1 virus infection. Notably, the anti-influenza activity of LS in infected mice might depend on the regulation of cytokines, particularly in cytokine storm associated cytokines, such as IFN-γ, IL-1β, IL-6, and TNF-α [17] . However, there is no exact evidence that LS is effective in the treatment of SARS-CoV-2 and its mechanisms of action remain obscure. Therefore, to study the antiviral activity of LS on SARS-CoV-2 and its potential effect in regulating the host's immune response, we evaluated the antiviral and anti-inflammatory efficiency of LS against a clinical isolate of SARS-CoV-2 from Guangzhou in vitro.

In this study, a comprehensive evaluation of the antiviral and anti-inflammatory activity of LS was performed in vitro with SARS-CoV-2 infection. It demonstrated that LS inhibited the replication of the virus in a dose-dependent manner and found that LS could reduce the number of viral particles. Moreover, LS could markedly decrease pro-inflammatory cytokine expression in infected human hepatocellular carcinoma cell lines (Huh-7), which may result in gaining a comprehensive understanding of the inhibition of LS against SARS-CoV-2 infection.

LS (lot: SA01004C) used in this study was produced and provided by Leiyunshang J o u r n a l P r e -p r o o f Pharmaceutical Group Co., Ltd. (Suzhou, China). The LS was triturated, 50 mg was prepared in at 4000 g for 15 min. The supernatant was filtered through a 0.22 μm syringe filter before use. In the previous study, the index components in LS were detected by high-performance liquid chromatography (HPLC). HPLC revealed that LS contained 0.12% gamabufotalin, 0.10% arenobufagin, 0.26% telocinobufagin, 0.21% desacetylcinobufotalin, 0.25% bufotalin, 0.41% cinobufotalin, 0.27% bufalin, 0.70% resibufogenin, 0.68% cinobufagin, 1.81% cholic acid, 0.27% anserine deoxycholic acid, and 0.23% deoxycholic acid [18] . Remdesivir was kindly provided by 

The African green monkey kidney epithelial (Vero E6) cells and human hepatocellular carcinoma cell lines (Huh-7) were purchased from ATCC. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. SARS-CoV-2 (Genebank accession no. MT123290.1) was clinical isolates from the First Affiliated Hospital of Guangzhou Medical University. The virus was propagated and adapted as previously described [19] . The 50% tissue culture infective dose (TCID50) of the virus was determined using the Reed Muench method (TCID50 = 10-6 /100 μL). Virus stocks were collected and stored at -80 °C. All the infection experiments were performed in a biosafety level-3 (BLS-3) laboratory.

The cytotoxic effects of LS or Remdesivir on Vero E6 and Huh-7 cells were evaluated by MTT assay [20] . Briefly, Vero E6 (5 × 10 4 cells/well) and Huh-7 (5 × 10 4 cells/well) cells grown in a monolayer in 96-well plates were rinsed with PBS followed by incubation with indicated concentrations of LS. After 72 h, the cells were stained with MTT solution at 0.5 mg/mL for 4 h.

The supernatants were then removed, and the formed formazan crystals were dissolved in 200 μL dimethyl sulfoxide (DMSO). The absorbance at 570 nm was determined using a Multiskan Spectrum reader (Thermo Fisher, USA).

To investigate the antiviral effects of LS against SARS-CoV-2, the CPE inhibition assay under the nontoxic concentration of LS was employed. Briefly, the Vero E6 cell monolayers were grown in 96-well plates and inoculated with 100 TCID50 of coronavirus strains at 37 C for 2 h.

The inoculum was removed, and the cells were subsequently incubated with indicated concentrations of LS and the positive control Remdesivir. Following 72 h of incubation, the infected cells showed 100% CPE under the microscope. The percentage of CPE in LS-treated cells was recorded. The 50% inhibition concentration (IC50) of the virus-induced CPE by LS was calculated as described and the selectivity index (SI) was determined from the CC50 to EC50 ratio [21] .

The plaque reduction assay was performed as previously described [21] . Briefly, Vero E6 cells monolayers in 6-well plates were rinsed with PBS and incubated with 100 plaque-forming unit (PFU) of SARS-CoV-2. Following 2 h of incubation, the inoculum was removed, and the cells were covered with agar/basic medium mixture, which contained 0.8% agar and indicated concentrations of LS or Remdesivir. The plates were then incubated at 37 ℃ for 48 h, followed by fixation in 4% formalin for 30 min. The overlays were then removed and stained with 0.1% crystal violet for 3 min. The plaques were visualized and counted. The IC50 of the virus-induced plaques by LS was calculated as described [21] .

To further identify the possible underlying mechanisms of LS, we used several drug concentrations, with high antiviral efficiency for subsequent experiments. The primers of TNF-α, IL-6, CCL-2/MCP-1, IL-1β, IL-8, CXCL-10/IP-10 and GAPDH genes ( Table 1) were designed by using Primer 5.0.

Briefly, Huh-7 cell monolayer in 12-well plates were rinsed with PBS and then exposed to samples via the SYBR Premix Ex Tap™ II (Takara Bio, Japan). The PCR data were analysed using the detection system (ABI PRISM® 7500 Real-time PCR system, Applied Biosystems Co., USA). The relative amount of PCR products was calculated using the 2−ΔΔCt method as previously described [22] . with 1% osmium tetroxide. The fixed cells were dehydrated through a series of ethanol and butanol mixtures [23] , and observed under the JSM-6340 SEM (JEOL, Japan).

The total proteins of the samples were extracted from the cells with 

All data in this study were analysed by using analysis of variance (ANOVA) with SPSS ver. 19 .0 (Armonk, NY, USA). Data were presented as the mean ± standard deviation (SD).

Differences in multiple groups were determined by one-way ANOVA with Tukey's honest J o u r n a l P r e -p r o o f significant difference (HSD) test. A P-value＜0.05 was considered statistically significant.

The cytotoxicity of LS in Vero E6 cells was first evaluated by non-radioactive cell 

To verify the antiviral efficacy on SARS-CoV-2, TEM assay was performed in the 

SARS-CoV-2 infection is known to be able to induce a strong inflammatory reaction, hallmarked by the production of cytokines and chemokines. Therefore, the expression of cytokines 

To further study whether the antiviral and anti-inflammation mechanisms induced by virus of LS was related to the inhibitory of NF-κB/MAPK signaling pathway activation, the expression of the key proteins related to the NF-κB/MAPK signaling pathway was examined. As shown in 

The number of infections caused by SARS-CoV-2 continues to rise sharply in the world [24, 25] .

The viral infection has widely and rapidly spread worldwide [26] . It is a major coronavirus infection, which threatens human life after SARS and MERS [27] . For this sudden and lethal disease, no specific antiviral drugs or vaccines have been developed, and supportive care and non-specific treatment of patients are currently the only options to ameliorate the symptoms [28] [29] [30] . Therefore, effective and safe antiviral agents are urgently needed. Currently, the use of TCM is a popular and acceptable therapy, and many TCM prescriptions have been proven to have obvious therapeutic LS is a TCM used to treat tonsillitis, influenza, pharyngitis, and mumps. However, the antiviral and anti-inflammatory effects induced by SARS-CoV-2 and the potential mechanisms of LS in treating viral pneumonia are less understood. Therefore, the potential antiviral and anti-inflammatory activities of LS induced by SARS-CoV-2 were investigated. In the present study, it was the first time to clarify that LS could not only inhibit SARS-CoV-2 infection, but also significantly suppress the inflammation caused by SARS-CoV-2 through a mechanism that involved the downregulation of inflammatory cytokines.

First, the effects of LS against SARS-CoV-2 in vitro by CPE assay and plaque reduction assay ( Figure 1 and Figure 2 ) were measured. The results showed that LS was able to protect cells from virus-induced cell death and inhibit the average size and plaque number in LS-treated cells in a dose-dependent manner. The SI index of LS reached 8.18 (Table 1 ). All these results confirmed that LS might be a potential antiviral drug for SARS-CoV-2. TEM has been a potent tool to observe virus entry, virus particle assembly, viral ultrastructure, and budding from the plasma membrane [31] . To understand the antiviral details of LS, TEM images were taken from each group It is reported that highly pathogenic coronaviruses such as SARS-CoV and MERS-CoV cause fatal pneumonia, which is mainly associated with rapid virus replication, massive inflammatory cell infiltration and elevated proinflammatory cytokine/chemokine responses. Although the pathophysiology of fatal pneumonia caused by highly pathogenic coronaviruses has not been completely understood, recent studies suggest a crucial role of cytokine storm in causing fatal pneumonia [32] . Early studies have shown that increased amounts of proinflammatory cytokines (e.g., IL-1β, IL-6, CXCL-10/IP-10, and CCL-2/MCP-1) in the serum of SARS patients [33] , which was similar to the serum patients with MERS with increased concentrations of proinflammatory cytokines (i.e., IFN-γ, TNF-α, IL-15, and IL-17) [34] . It also reported that the expression of the cytokine storm in the NCIP patients in ICU than those in non-ICU patients [7] . Therefore, the Since the SARS syndrome is characterized by an uncontrolled inflammatory response and NF-κB is the major transcription factor activated in acute respiratory distress syndrome (ARDS) [35] .

Similar to SARS-CoV, SARS-CoV-2 can also cause severe respiratory illness and even death.

NF-кB plays an important role in mediating inflammation, immune responses, and other cellular activities [36] . Activation of NF-кB can induce cytokines production, and these cytokines can react upon in turn and they produce a positive autoregulatory loop and exacerbate the inflammatory response [37] . Therefore, to understand the molecular mechanism of LS against virus infection, the regulation of the NF-кB/MAPK signaling pathway contributes to the alleviation of inflammation.

The results showed that SARS-CoV-2 activated the NF-кB /MAPK signaling pathway and LS could significantly decrease SARS-CoV-2-induced activation of p-NF-κB p65, p-IκBα, and p-p38 MAPK and increase the expression of the IκBα ( Figure 5 ). We inferred that the underlying mechanism of LS is to impair the upregulated proinflammatory cytokines induced by SARS-CoV-2 via inhibiting the activity of NF-кB/MAPK signaling pathway. The change of cytokine profiles suggested that LS might have a potential effect on the inhibition of cytokine storm induced by SARS-CoV-2.

In conclusion, our results revealed that LS could significantly protect cells from virus-induced 

A novel coronavirus associated with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Outbreak of a novel coronavirus

China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22

Coronaviruses-drug discovery and therapeutic options

Xuexun Fang, Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo

Effect of Lianhua Qingwen capsule on immunity of mice infected with flu virus

Comparative Study on the Antivirus Activity of Shuang-Huang-Lian Injectable Powder and Its Bioactive Compound Mixture against Human Adenovirus III In Vitro

Pharmacological study of liushen pill

The research of Liu shen pills

Study on the effect of Liushen pill anti-adenovirus in vitro

Liu Shen Wan inhibits influenza a virus and excessive virus-induced inflammatory response via suppression of TLR4/NF-κB signaling pathway in vitro and in vivo

A Novel Coronavirus J o u r n a l P r e -p r o o f from Patients with Pneumonia in China

Korean Scutellaria baicalensis water extract inhibits cell cycle G1/S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells

A simple method of estimating fifty percent endpoints

A new mathematical model for relative quantification in real-time RT-PCR

Scanning electron microscope examination of epithelial cells infected with enveloped viruses

Distribution of 2019-nCoV infection

WHO. Novel coronavirus (2019-nCoV) situation report-27

China Medical Treatment Expert Group for Covid-19., Clinical characteristics of 2019 novel coronavirus infection in China

China coronavirus: WHO declares international emergency as death toll exceeds 200

Therapeutic options for the 2019 novel coronavirus (SARS-CoV-2)

Clinical evidence does not support corticosteroid treatment for SARS-CoV-2 lung injury

Reducing mortality from: J o u r n a l P r e -p r o o f host-directed therapies should be an option

Modern uses of electron microscopy for detection of viruses

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Clinical and laboratory findings of SARS in Singapore

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Transcriptional mechanisms of acute lung injury

Signaling via the NF-κB system

NF-κB and virus infection: who controls whom

The authors declare no conflict of interest.